Suppr超能文献

敌友难辨?端粒酶作为癌症和心血管疾病的药物靶点

Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

作者信息

Ait-Aissa Karima, Ebben Johnathan D, Kadlec Andrew O, Beyer Andreas M

机构信息

Department of Medicine, Medical College of Wisconsin, United States; Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, United States.

Department of Pharmacology & Toxicology, Medical College of Wisconsin,, United States; Cancer Center, Medical College of Wisconsin, United States.

出版信息

Pharmacol Res. 2016 Sep;111:422-433. doi: 10.1016/j.phrs.2016.07.003. Epub 2016 Jul 6.

Abstract

Aging, cancer, and chronic disease have remained at the forefront of basic biological research for decades. Within this context, significant attention has been paid to the role of telomerase, the enzyme responsible for lengthening telomeres, the nucleotide sequences located at the end of chromosomes found in the nucleus. Alterations in telomere length and telomerase activity are a common denominator to the underlying pathology of these diseases. While nuclear-specific, telomere-lengthening effects of telomerase impact cellular/organismal aging and cancer development, non-canonical, extra-nuclear, and non-telomere-lengthening contributions of telomerase have only recently been described and their exact physiological implications are ill defined. Although the mechanism remains unclear, recent reports reveal that the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), regulates levels of mitochondrial-derived reactive oxygen species (mtROS), independent of its established role in the nucleus. Telomerase inhibition has been the target of chemotherapy (directed or indirectly) for over a decade now, yet no telomerase inhibitor is FDA approved and few are currently in late-stage clinical trials, possibly due to underappreciation of the distinct extra-nuclear functions of telomerase. Moreover, evaluation of telomerase-specific therapies is largely limited to the context of chemotherapy, despite reports of the beneficial effects of telomerase activation in the cardiovascular system in relation to such processes as endothelial dysfunction and myocardial infarction. Thus, there is a need for better understanding of telomerase-focused cell and organism physiology, as well as development of telomerase-specific therapies in relation to cancer and extension of these therapies to cardiovascular pathologies. This review will detail findings related to telomerase and evaluate its potential to serve as a therapeutic target.

摘要

几十年来,衰老、癌症和慢性疾病一直是基础生物学研究的前沿领域。在此背景下,人们对端粒酶的作用给予了极大关注,端粒酶是一种负责延长端粒的酶,端粒是位于细胞核中染色体末端的核苷酸序列。端粒长度和端粒酶活性的改变是这些疾病潜在病理的共同特征。虽然端粒酶的端粒延长作用具有核特异性,会影响细胞/机体衰老和癌症发展,但端粒酶的非经典、核外和非端粒延长作用直到最近才被描述,其确切的生理意义也尚不明确。尽管机制尚不清楚,但最近的报告显示,端粒酶的催化亚基端粒酶逆转录酶(TERT)可调节线粒体衍生的活性氧(mtROS)水平,这与其在细胞核中已确立的作用无关。十多年来,端粒酶抑制一直是化疗(直接或间接)的靶点,但目前尚无FDA批准的端粒酶抑制剂,且很少有处于后期临床试验阶段,这可能是由于对端粒酶独特的核外功能认识不足。此外,尽管有报道称端粒酶激活在心血管系统中对内皮功能障碍和心肌梗死等过程具有有益作用,但端粒酶特异性疗法的评估在很大程度上仅限于化疗背景。因此,有必要更好地了解以端粒酶为重点的细胞和机体生理学,以及开发针对癌症的端粒酶特异性疗法,并将这些疗法扩展到心血管疾病。本综述将详细介绍与端粒酶相关的研究结果,并评估其作为治疗靶点的潜力。

相似文献

4
Telomere biology of pediatric cancer.儿童癌症的端粒生物学
Cancer Invest. 2007 Apr-May;25(3):197-208. doi: 10.1080/07357900701208683.
6
Telomeres and telomere dynamics: relevance to cancers of the GI tract.端粒和端粒动力学:与胃肠道癌症的相关性。
Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):733-48. doi: 10.1586/17474124.2013.848790.
9

引用本文的文献

5
Telomerase therapy attenuates cardiotoxic effects of doxorubicin.端粒酶治疗可减轻多柔比星的心脏毒性作用。
Mol Ther. 2021 Apr 7;29(4):1395-1410. doi: 10.1016/j.ymthe.2020.12.035. Epub 2021 Jan 1.
8
Telomeres as Therapeutic Targets in Heart Disease.端粒作为心脏病的治疗靶点
JACC Basic Transl Sci. 2019 Nov 25;4(7):855-865. doi: 10.1016/j.jacbts.2019.05.009. eCollection 2019 Nov.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验